(Q37546018)

20 August 2017

1 reference

title

Azacitidine for the treatment of myelodysplastic syndrome (English)

1 reference

20 August 2017

2

Jorge Cortes

1 reference

20 August 2017

Vince D Cataldo

1

1 reference

20 August 2017

Alfonso Quintás-Cardama

series ordinal

3

1 reference

20 August 2017

publication date

1 July 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

875-884

1 reference

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

20 August 2017

cites work

1 reference

Myelodysplastic syndromes--coping with ineffective hematopoiesis

21 January 2018

1 reference

The cytogenetics of myelodysplastic syndromes

21 January 2018

1 reference

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

21 January 2018

1 reference

Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition

21 January 2018

1 reference

5-Azacytidine in Refractory Acute Leukemia

21 January 2018

1 reference

Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

21 January 2018

1 reference

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

21 January 2018

1 reference

Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells

21 January 2018

1 reference

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

21 January 2018

1 reference

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

DNA methylation as a therapeutic target in cancer

21 January 2018

1 reference

Introduction: emerging role of epigenetic therapy: focus on decitabine.

21 January 2018

1 reference

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

21 January 2018

1 reference

Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.

21 January 2018

1 reference

A pilot pharmacokinetic study of oral azacitidine

21 January 2018

1 reference

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

21 January 2018

1 reference

Treatment of myelodysplastic syndromes with 5-azacytidine

21 January 2018

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.61

1 reference

20 August 2017

1 reference